Last reviewed · How we verify
standard dose ARA-C
ARA-C (cytarabine) is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.
ARA-C (cytarabine) is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.
At a glance
| Generic name | standard dose ARA-C |
|---|---|
| Also known as | standard dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2) |
| Sponsor | National Research Center for Hematology, Russia |
| Drug class | Nucleoside analog antimetabolite |
| Target | DNA polymerase; ribonucleotide reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
ARA-C is a nucleoside analog that mimics cytidine and is phosphorylated intracellularly to its active triphosphate form. This active metabolite competes with natural deoxycytidine triphosphate for incorporation into DNA during replication. Once incorporated, it causes chain termination and prevents further DNA synthesis, triggering apoptosis in rapidly dividing cells, particularly hematopoietic malignancies.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Chronic myeloid leukemia (CML) in blast crisis
- Lymphoma
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Hepatotoxicity
- Neurotoxicity (at high doses)
- Infection
- Diarrhea
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Revumenib in Combination With 7+3 + Midostaurin in AML (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard dose ARA-C CI brief — competitive landscape report
- standard dose ARA-C updates RSS · CI watch RSS
- National Research Center for Hematology, Russia portfolio CI